Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2016-10-10 Earnings Release
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 95% confidence The document is a press release dated October 10, 2016, announcing positive Phase 2 trial results (CABOSUN) for cabozantinib versus sunitinib in advanced renal cell carcinoma, presented at the ESMO 2016 congress. It details efficacy data (PFS, ORR) and safety profiles, and includes quotes from investigators and company management (Ipsen CEO). Crucially, it states that Exelixis plans to submit a Supplemental New Drug Application (sNDA) based on these results and that Ipsen is evaluating next steps. This content strongly aligns with an Earnings Release (ER) or a detailed press announcement accompanying major clinical data, which often precedes formal regulatory filings. Since it is a detailed announcement of financial/clinical performance highlights and future regulatory plans, it fits best as an Earnings Release (ER) or potentially an Investor Presentation (IP) if it were structured as slides, but given the format and focus on results and future strategy, ER is the closest fit among the options for a major corporate update on performance/pipeline progress. It is not a full 10-K, an Audit Report, or a simple Report Publication Announcement (RPA) as it contains substantial analysis and data, not just a notice of publication. FY 2016
2016-10-10 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is an announcement from Ipsen dated September 27, 2016, detailing data presentations for several of its drugs (Cabozantinib, Lanreotide, Telotristat ethyl) at the European Society for Medical Oncology (ESMO) 2016 congress. It lists specific presentation abstracts (e.g., [LBA30], [774PD]), times, and locations. It also includes boilerplate information about the company and forward-looking statements. This content is typical of a press release announcing participation in a major industry conference, often released shortly before or during the event to inform investors and the public about upcoming scientific disclosures. It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). Since it is a specific announcement about scientific data being presented at a medical conference, it fits best under the general category of Investor/Regulatory communication that doesn't fit the highly specific financial codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a non-financial, non-management specific press release detailing scientific updates, although 'Investor Presentation' (IP) is related to the content, the document itself is an announcement *about* presentations, not the presentation slides themselves. However, RNS serves as the best general regulatory/announcement category when other specific codes fail. Given the context of scientific data disclosure, RNS is the most suitable general announcement code.
2016-09-27 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is a press release from Ipsen, dated September 27, 2016, announcing the presentation of clinical data for several of its drugs (Cabozantinib, Lanreotide, Telotristat ethyl) at the 2016 European Society for Medical Oncology (ESMO) congress. It details specific presentation times, poster numbers, and session types (oral presentation, poster discussion, poster presentation). This content is typical of an announcement detailing scientific or clinical data dissemination, often preceding or accompanying a major conference. It is not a full Annual Report (10-K), an Earnings Release (ER), or a comprehensive Interim Report (IR). It is a detailed announcement about scientific findings being presented, which aligns best with an Investor Presentation (IP) if it were the presentation itself, but since it is an announcement *about* presentations at a conference, it functions as a specific type of corporate communication. Given the focus on clinical data presentation schedules and scientific updates, it is most closely related to Investor Presentation materials or a specialized regulatory filing. However, since it is a press release detailing scientific data to be presented at a medical conference, and not a formal financial report or a general regulatory filing (RNS), it fits best under the category of Investor Presentation (IP) as it is material intended for investors/analysts regarding pipeline progress, or potentially a Regulatory Filing (RNS) if no better fit exists. Since it details specific scientific data points and presentations, it is more targeted than a general RNS. It is not a Call Transcript (CT) or a Management Discussion & Analysis (MDA). Given the context of presenting clinical trial data, it is highly relevant to investors, making 'Investor Presentation' (IP) a strong candidate, even though it's structured as a press release announcing the presentations. If the document *were* the actual presentation slides, IP would be certain. As an announcement of data being presented, it serves a similar informational purpose. I will classify it as Investor Presentation (IP) because the core content is scientific/clinical data updates relevant to investment decisions, which is the primary function of an IP, even if delivered via a press release format detailing conference schedules.
2016-09-27 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 92% confidence The document text is a press release dated September 14, 2016, announcing that the European Commission has approved Ipsen's drug, Cabometyx™, for advanced renal cell carcinoma. It details clinical trial results (METEOR trial), mechanism of action, and provides background information on the drug and the company. This format—a formal announcement of a significant corporate/product event, often released to the public and regulatory bodies simultaneously—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement about regulatory approval and clinical data, it is more specific than a general RNS. However, it is not a comprehensive financial report (10-K or IR), a management discussion (MDA), or a transcript (CT). In the context of pharmaceutical/biotech filings, major regulatory approvals are often disseminated via press release, which frequently aligns with the 'Earnings Release' category when it contains key performance/product milestones, or sometimes falls under 'Regulatory Filings' (RNS) if it's purely informational and not tied to a quarterly earnings cycle. Given the content is a major product approval announcement with supporting data, and it is not a comprehensive financial report, it best fits the 'Earnings Release' (ER) category as it signals a major commercial milestone, or 'Regulatory Filing' (RNS) as a general announcement. Since the definitions prioritize specific financial reports, and this is a news announcement about a regulatory event, 'ER' (Earnings Release) is often used for major positive news releases, but 'RNS' (Regulatory Filings) is the safest catch-all for non-standard, material announcements. Given the structure is a press release announcing a regulatory decision and clinical data, and it is not a quarterly/annual report, I will classify it as an Earnings Release (ER) as it drives future revenue expectations, or RNS. Given the focus on regulatory approval and clinical data rather than quarterly financial figures, RNS is a strong candidate, but ER often covers major product milestones. I will lean towards ER as it is a significant commercial event announcement, similar to how companies use ERs for major pipeline updates outside of standard reporting periods. However, since it is a regulatory approval announcement, RNS is also highly appropriate. Given the options, and the fact that it is a press release announcing a regulatory event, RNS is the most neutral and accurate fit if it doesn't contain explicit quarterly earnings figures. Since it is a major announcement, I will select ER as it signals a major commercial event, which is often grouped with ERs. FY 2016
2016-09-14 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated September 14, 2016, announcing that the European Commission has granted marketing authorization for Ipsen's drug, Cabometyx™, for advanced renal cell carcinoma. It details clinical trial results (METEOR study), mechanism of action, and provides company background. This type of announcement, focusing on a significant regulatory milestone (marketing authorization) and providing key clinical/financial context, is characteristic of a press release detailing a major corporate event or result. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a specific voting/insider filing, it fits best as a general corporate announcement. Given the focus on a major regulatory approval and the presentation of key efficacy data, it is most closely aligned with an Earnings Release (ER) in terms of format (press release announcing results/milestones) or potentially a Regulatory Filing (RNS) if it were a mandatory filing, but ER often covers major product news. However, since the core event is a regulatory approval and the text is a detailed announcement, it is not a short 'Report Publication Announcement' (RPA). It is a comprehensive announcement of a major business/regulatory event. In the context of the provided definitions, this is a major corporate announcement that doesn't fit the specific financial report codes (10-K, IR, MRQ). It is most similar to an Earnings Release (ER) in structure (press release format announcing key achievements/data) or a general Regulatory Filing (RNS). Given the focus on a product approval and associated data, ER is a strong candidate if this is considered a 'results' announcement, but RNS is the general fallback for significant, non-standard announcements. Since it is a detailed announcement of a major regulatory achievement, and not a standard financial report, RNS (Regulatory Filings/General Announcement) is the most appropriate general category for significant, non-standard corporate news that isn't explicitly covered elsewhere.
2016-09-14 French
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and references Article 223-16 of the AMF General Regulations. It provides a monthly update on the total number of shares and voting rights as of August 31, 2016. This specific type of periodic disclosure regarding share capital structure and voting rights does not perfectly align with the primary definitions (like 10-K, ER, or DIV). However, it is a specific regulatory disclosure concerning capital structure and ownership rights. Given the options, it is closest to a general regulatory filing or a specific capital/share announcement. Since it details the total number of shares and voting rights, it relates closely to share capital changes, but it is a recurring monthly disclosure rather than a one-off event like a share issue (SHA) or a director's dealing (DIRS). Because it is a specific, recurring regulatory disclosure that doesn't fit the other specialized categories, the most appropriate fallback is Regulatory Filings (RNS), although it shares characteristics with Share Issue/Capital Change (SHA) in terms of subject matter. Given the context of monthly voting rights disclosure, RNS is the best fit as a general regulatory announcement.
2016-09-09 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.